# Molecular Pathology and Tissue Resource

> **NIH NIH P50** · UT SOUTHWESTERN MEDICAL CENTER · 2020 · $192,861

## Abstract

Pathology Core (Core B) Project Summary/Abstract
The Molecular Pathology and Tissue Resources Core will provide routine and innovative tissue resources and
materials essential for achieving the aims of the SPORE projects. Routine materials include tumors, non-
malignant lung specimens, tumor cell lines, and clinical annotation, all of which have been obtained with informed
consent and measures to ensure patient confidentiality. Over 6,000 tumors including tumors on clinically
annotated tissue microarrays (TMAs), 300 lung cancer cell lines of all histologic types, and over 180 lung tumor
patient-derived and circulating tumor cell-derived xenografts (PDXs/CDXs) are available to investigators. Many
of these samples have been distributed to our SPORE investigators, as well as other investigators at our own
and outside institutions (including other SPOREs). These partnerships have fueled multiple lung cancer
translational research collaborations, and have generated over 380 publications in the last ten years. In addition
to important clinical and histologic annotation, the genomic, molecular, and immune microenvironment profiling
of these samples provide important Human Endpoints for correlative data and synergy, both within the UT Lung
SPORE and as components of other lung cancer translational research. Given the increasing importance of
immunotherapy for lung cancer, the Pathology Core has developed methods to provide state of the art immune
profiling annotation. Additionally, the Core has participated in collection of patient samples from the MDACC
ImmunogenomiC prOfiling of NSCLC (ICON) and NEOadjuvant STudy of induction checkpoint blockade for
Resectable stage I-IIIA NSCLC (NEOSTAR) clinical trials. Our Aim 1 is to collect, process, store, catalog and
distribute tissues, cell lines and blood specimens, both malignant and non- malignant, tumor xenografts, and
relevant clinico-pathologic and molecular data, as requested by the various component projects of the SPORE
program; we will use IRB-approved protocols, informed consent, and measures to protect subject confidentiality.
Aim 2 is to develop and utilize innovative and routine tissue and cell line resources that will aid in the successful
completion of the SPORE program aims; these include development of new tumor cell lines, additional lung
cancer TMA resources, molecular analysis of tumors and liquid biopsy, and comprehensive immune profiling of
tissues. Aim 3 is to perform, interpret, analyze, and deposit tissue-based molecular and immune analysis
methodologies in close collaboration with the component Projects, DRP, CEP, and Data Sciences Core of the
SPORE program to achieve their approved aims. Within these aims, the Pathology Core will play a crucial role
in promoting vertical and horizontal collaborations among our own SPORE investigators, investigators at other
Lung Cancer SPORE sites, and other investigators at our own and other institutions. All of our SPORE projects
will use Core B ma...

## Key facts

- **NIH application ID:** 10023863
- **Project number:** 2P50CA070907-21A1
- **Recipient organization:** UT SOUTHWESTERN MEDICAL CENTER
- **Principal Investigator:** Justin A. Bishop
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $192,861
- **Award type:** 2
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10023863

## Citation

> US National Institutes of Health, RePORTER application 10023863, Molecular Pathology and Tissue Resource (2P50CA070907-21A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10023863. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*